SCHEMBL16268552

SCHEMBL16268552

Cc1c(I)c(C(=O)O)nn1C

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.38
ALDH1A1 P00352 4/20 0.38
POLB P06746 5/20 0.38
KDM4E B2RXH2 4/20 0.35
HPGD P15428 2/20 0.35
LMNA P02545 2/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 3/20 0.33
ALPL P05186 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
RAB9A P51151 3/20 0.33
NPC1 O15118 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
MEN1 O00255 2/20 0.32
GRN P28799 1/20 0.32
SORT1 Q99523 1/20 0.32
BAZ2B Q9UIF8 1/20 0.32
APOBEC3A P31941 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4594309 0.78 ALDH1A1 (0.40) GAAALDH1A1POLBKDM4EHPGD
SCHEMBL8308094 0.77 POLB (0.59) GAAALDH1A1POLBKDM4EHPGD
SCHEMBL16797981 0.75 GAA (0.39) GAAALDH1A1POLBKDM4EHPGD
SCHEMBL3140977 0.75 RAB9A (0.49) GAAALDH1A1POLBKDM4EHPGD
SCHEMBL6079387 0.72 HCAR2 (0.38) GAAALDH1A1POLBKDM4EHPGD
SCHEMBL18603294 0.71 KDM4E (0.43) GAAALDH1A1POLBKDM4ELMNA
SCHEMBL30061569 0.71 RAB9A (0.42) GAAALDH1A1POLBKDM4EHPGD
SCHEMBL13799637 0.71 GABRR1 (0.37) GAAALDH1A1POLBKDM4ESMN1; SMN2
SCHEMBL5273884 0.69 ALDH1A1 (0.55) GAAALDH1A1HTTKMT2AALPL
SCHEMBL253745 0.68 MAPT (0.49) ALDH1A1POLBLMNAHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070924-A1 INDAZOLE MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS INC (US) 2026-03-12 US disclosed
EP-4688154-A1 MORPHOLINE OREXIN RECEPTOR ANTAGONISTS BIAL - Portela & Ca., S.A. (PT) 2026-02-11 EP disclosed
EP-4688155-A1 MORPHOLINE OREXIN RECEPTOR ANTAGONISTS Bial-Portela & CA, S.A. (PT) 2026-02-11 EP disclosed
EP-4536225-A1 INDAZOLE MACROCYCLES AND THEIR USE Blossomhill Therapeutics, Inc. (US) 2025-04-16 EP disclosed
WO-2025023852-A1 MORPHOLINE OREXIN RECEPTOR ANTAGONISTS BIAL - PORTELA & CA., S.A. (PT) 2025-01-30 WO disclosed
WO-2025023851-A1 MORPHOLINE OREXIN RECEPTOR ANTAGONISTS BIAL - PORTELA & CA., S.A. (PT) 2025-01-30 WO disclosed
CN-119325379-A Indazole macrocyclic compounds and uses thereof 荣山医药股份有限公司 2025-01-17 CN disclosed
WO-2023240140-A1 INDAZOLE MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
WO-2023240140-A1 INDAZOLE MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
EP-3004110-A1 PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE Novartis AG (CH) 2016-04-13 EP disclosed
WO-2014191896-A1 PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2014-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070924-A1 INDAZOLE MACROCYCLES AND THEIR USE NR0B2, NR0B1, ESRRA GAA 4258/4885ALDH1A1 1008/4885POLB 1871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.